High-Dose Lanreotide in the Treatment of Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: A Case Report

High-Dose Lanreotide in the Treatment of Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: A Case Report

Pancreatic neuroendocrine tumors (NETs), including poorly differentiated carcinomas (NECs), are rarely encountered. The majority of these tumors do not secrete excess hormones, but functioning NETs produce large amounts of vasoactive peptides and may cause carcinoid syndrome. Synthetic somatostatin...

Full description

Bibliographic Details
Main Authors: Frank Van Fraeyenhove, Nathalie Meireson, Luc Terriere, Paul Willemsen, Jan Kunnen, Caroline Mattelaer, Frank Van Acker, Dirk Schrijvers
Format: Article
Language:English
Published: Karger Publishers 2014-03-01
Series:Case Reports in Oncology
Subjects:
Neuroendocrine tumor
Pancreas
High-dose lanreotide
Carcinoid
Online Access:http://www.karger.com/Article/FullText/360732

Similar Items

Similar Items